The Theraprutic Effect of New Drugs for Hepatocellular Carcinoma
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 2,500
- 试验地点
- 1
- 主要终点
- liver cancer response of evaluation according to RECIST and mRECIST criteria
研究概览
简要总结
Hepatocellular carcinoma (HCC) is one of the most significant cancers in our country. Since 2019, many first-line and second-line therapeutic agents for HCC have been introduced. This study aims to evaluate the treatment outcomes of HCC patients in our hospital from 2019 to 2024 who received therapies other than the traditional sorafenib (Nexavar). The included drugs are Pembrolizumab, Atezolizumab (Tecentriq), Nivolumab, Lenvatinib, and Regorafenib (Stivarga). The study will collect clinical data from treated-cases with these novel agents after 2019 and integrate biochemical and pathological indicators to analyze prognostic outcomes, including overall survival, progression-free survival, and complications.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Other
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hepatocellular carcinoma participants who received treatment at National Taiwan University Hospital between January 1, 2019, and June 30, 2026, and had used the following medications.
- •Pembrolizumab /keytruda
- •Atezolizumab / Tecentriq
排除标准
- 未提供
结局指标
主要结局
liver cancer response of evaluation according to RECIST and mRECIST criteria
时间窗: 3 years
次要结局
未报告次要终点